Literature DB >> 533258

Bronchial secretion levels of amikacin.

W L Dull, M R Alexander, J E Kasik.   

Abstract

Amikacin was given to 14 noninfected men as three consecutive intramuscular injections (7.5 mg/kg) at 12-h intervals. Serum and bronchial secretion specimens were obtained at various times during flexible fiberoptic bronchoscopy after the final dose. Serum and bronchial secretion concentrations obtained between 1.5 and 2.0 h after the final dose ranged from 17 to 40 mug/ml and 2.3 to 8.4 mug/ml with a mean of 23.7 +/- 2.9 and 5.23 +/- 1.5 mug/ml, +/-1 standard error of the mean, respectively. The highest bronchial secretion concentration in each subject correlated with the highest serum concentration (r = 0.83, P < 0.001), and all concurrent serum and bronchial secretion concentrations demonstrated a significant correlation (r = 0.82, P < 0.001). Clearance occurred at the same rate (half-life serum = 2.84 h; half-life of bronchial secretion = 2.60 h, P > 0.5). The mean bronchial secretion concentration of the 15 specimens obtained more than 7 h after the final dose was less than 1.0 mug/ml, with a range from 0.3 to 1.6 mug/ml. It is concluded that amikacin may achieve minimal inhibitory concentrations for many gram-negative bacteria in the bronchial secretions of noninfected patients 1 to 2 h after the final dose. However, levels fall below the reported minimal inhibitory concentrations against negative bacteria 6 to 7 h after the final dose. Furthermore, bronchial secretion levels may never reach the minimal inhibitory concentration against Pseudomonas aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 533258      PMCID: PMC352950          DOI: 10.1128/AAC.16.6.767

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Penetration of tobramycin into infected extravascular fluids and its therapeutic effectiveness.

Authors:  W H Hall; D N Gerding; E A Schierl
Journal:  J Infect Dis       Date:  1977-06       Impact factor: 5.226

2.  Pharmacokinetic study of beta-lactam antibiotics in bronchial secretions.

Authors:  E Bergogne-Berezin; C Morel; Y Benard; G Berthelot; H Kafe
Journal:  Scand J Infect Dis Suppl       Date:  1978

3.  The concentration of tobramycin in bronchial secretions.

Authors:  M R Alexander; E M Berglund; J E Kasik; A Fox; W M Chinn
Journal:  Chest       Date:  1979-06       Impact factor: 9.410

4.  Amikacin treatment of pulmonary infections involving gentamicin-resistant gram-negative bacilli.

Authors:  J G Bartlett
Journal:  Am J Med       Date:  1977-06       Impact factor: 4.965

5.  Amikacin in the treatment of gram-negative pneumonia.

Authors:  G M Trenholme; P P McKellar; N Rivera; S Levin
Journal:  Am J Med       Date:  1977-06       Impact factor: 4.965

6.  Controlled comparison of amikacin and gentamicin.

Authors:  C R Smith; K L Baughman; C Q Edwards; J F Rogers; P S Lietman
Journal:  N Engl J Med       Date:  1977-02-17       Impact factor: 91.245

7.  Susceptibility of recently isolated bacteria to amikacin in vitro: comparisons with four other aminoglycoside antibiotics.

Authors:  M Finland; C Garner; C Wilcox; L D Sabath
Journal:  J Infect Dis       Date:  1976-11       Impact factor: 5.226

8.  Endotracheally administered antibiotics for gram-negative bronchopneumonia.

Authors:  J Klastersky; F Carpentier-Meunier; L Kahan-Coppens; J P Thys
Journal:  Chest       Date:  1979-05       Impact factor: 9.410

9.  [Tobramycin Concentration in Human Lung Tissue (author's transl)].

Authors:  U Kroening; S Liebig; M Wundschock
Journal:  Infection       Date:  1978       Impact factor: 3.553

10.  Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa.

Authors:  R M Kluge; H C Standiford; B Tatem; V M Young; W H Greene; S C Schimpff; F M Calia; R B Hornick
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

View more
  12 in total

Review 1.  Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness.

Authors:  Rina Mehrotra; Raffaele De Gaudio; Mark Palazzo
Journal:  Intensive Care Med       Date:  2004-11-05       Impact factor: 17.440

Review 2.  Drug treatment of pneumonia in the hospital. What are the choices?

Authors:  M Aoun; J Klastersky
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 3.  Drug monitoring in nonconventional biological fluids and matrices.

Authors:  S Pichini; I Altieri; P Zuccaro; R Pacifici
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

4.  Penetration of cefotaxime into respiratory secretions.

Authors:  R B Fick; M R Alexander; R A Prince; J E Kasik
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

5.  Quantification of amikacin in bronchial epithelial lining fluid in neonates.

Authors:  C Tayman; M N El-Attug; E Adams; A Van Schepdael; A Debeer; K Allegaert; A Smits
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

6.  Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection.

Authors:  Beatriz E Ferro; Shashikant Srivastava; Devyani Deshpande; Jotam G Pasipanodya; Dick van Soolingen; Johan W Mouton; Jakko van Ingen; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

7.  Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily versus twice daily.

Authors:  C Santré; H Georges; J M Jacquier; O Leroy; C Beuscart; D Buguin; G Beaucaire
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

8.  Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  R K Scribner; M I Marks; A H Weber; M M Tarpay; D F Welch
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

9.  Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model.

Authors:  Beatriz E Ferro; Shashikant Srivastava; Devyani Deshpande; Carleton M Sherman; Jotam G Pasipanodya; Dick van Soolingen; Johan W Mouton; Jakko van Ingen; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

Review 10.  Clinical pharmacokinetics in infants and children. A reappraisal.

Authors:  G L Kearns; M D Reed
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.